Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
United Therapeutics Corp. (UTHR)
:UTHR
Holding UTHR?
Track your performance easily
UTHR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$208.62 - $417.82
Previous CloseN/A
Volume58.00K
Average Volume (3M)285.34K
Market Cap
$16.36B
Enterprise Value$14.42B
Total Cash (Recent Filing)$1.05B
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)15.8
Beta0.64
Next Earnings
Feb 19, 2025EPS Estimate
6.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)22.77
Shares Outstanding44,644,520
10 Day Avg. Volume258,878
30 Day Avg. Volume285,339
Standard Deviation0.10
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.93
Price to Cash Flow (P/CF)10.80
P/FCF Ratio13.60
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue5.23
Enterprise Value/Gross Profit6.97
Enterprise Value/Ebitda9.41
Forecast
1Y Price Target
$407.91Price Target Upside11.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
United Therapeutics News
PremiumCompany Announcements
United Therapeutics to Present at J.P. Morgan Conference
Bulls Say, Bears Say
Bulls Say
Market ExpansionThe company has grown its prescriber base by nearly 15%, and importantly UTHR noted that 40% of new prescribers are ILD physicians.
Market LeadershipTyvaso is the most prescribed prostacyclin in the US, and no near-term erosion in Tyvaso's market share in PAH is expected.
Revenue GrowthTyvaso revenues remain strong with DPI driving revenue growth.
Bears Say
Financial PerformanceThe bottom line missed expectations due to a one-time legal expense related to ongoing litigation.
Product SalesRemodulin sales are expected to show only minimal growth year-over-year and a decline quarter-over-quarter.
Regulatory ChallengesIt is unclear that Liquidia's potential challenge to the FDA's decision would be resolved before the end of the exclusivity period.
---
Ownership Overview
7.08% Insiders
25.89% Mutual Funds
0.54% Other Institutional Investors
38.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UTHR FAQ
What was United Therapeutics Corp.’s price range in the past 12 months?
United Therapeutics Corp. lowest stock price was $208.62 and its highest was $417.81 in the past 12 months.
What is United Therapeutics Corp.’s market cap?
United Therapeutics Corp.’s market cap is $16.36B.
When is United Therapeutics Corp.’s upcoming earnings report date?
United Therapeutics Corp.’s upcoming earnings report date is Feb 19, 2025 which is in 32 days.
How were United Therapeutics Corp.’s earnings last quarter?
United Therapeutics Corp. released its earnings results on Oct 30, 2024. The company reported $6.39 earnings per share for the quarter, missing the consensus estimate of $6.523 by -$0.133.
Is United Therapeutics Corp. overvalued?
According to Wall Street analysts United Therapeutics Corp.’s price is currently Undervalued.
Does United Therapeutics Corp. pay dividends?
United Therapeutics Corp. does not currently pay dividends.
What is United Therapeutics Corp.’s EPS estimate?
United Therapeutics Corp.’s EPS estimate is 6.58.
How many shares outstanding does United Therapeutics Corp. have?
United Therapeutics Corp. has 44,644,520 shares outstanding.
What happened to United Therapeutics Corp.’s price movement after its last earnings report?
United Therapeutics Corp. reported an EPS of $6.39 in its last earnings report, missing expectations of $6.523. Following the earnings report the stock price went up 2.438%.
Which hedge fund is a major shareholder of United Therapeutics Corp.?
Among the largest hedge funds holding United Therapeutics Corp.’s share is Polaris Capital Management LLC. It holds United Therapeutics Corp.’s shares valued at 51M.
---
United Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$407.91 (11.33% Upside)
$407.91 (11.33% Upside)
Blogger Sentiment
Bullish
UTHR Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 102.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 3.0%
Last 30 Days ▲ 3.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.49%
12-Months-Change
Fundamentals
Return on Equity
18.81%
Trailing 12-Months
Asset Growth
1.42%
Trailing 12-Months
Company Description
United Therapeutics Corp.
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
---
UTHR Company Deck
---
UTHR Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with significant revenue growth across multiple products and the successful completion of a share repurchase program. However, there were some challenges, such as a litigation accrual and a slight decline in international Remodulin revenue.Read More>---
UTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
---
UTHR Stock 12 Month Forecast
Average Price Target
$407.91
▲(11.33% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Neurocrine
―
Vertex Pharmaceuticals
―
Regeneron
―
Incyte
―
Best Analysts Covering UTHR
1 Year
1 Year Success Rate
12/14 ratings generated profit
1 Year Average Return
+23.48%
assigned a buy rating 3 months ago
Copying Tiago Fauth's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +23.48% per trade.
---